Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

Richard Warren, ¹April Armstrong, ²Melinda Gooderham, ³Bruce Strober, ⁴Diamant Thaçi, ⁵Shinichi Imafuku, ⁶Howard Sofen, ⁷Lynda Spelman, ⁸Neil Korman, ⁹Min Zheng, ¹⁰Elizabeth Colston, ¹¹John Throup, ¹²Sudeep Kundu, ¹³Renata Kisa, ¹⁴Subhashis Banerjee, ¹⁵Andrew Blauvelt ¹

¹University of Manchester, Manchester, UK; ²University of Southern California, Los Angeles, CA, USA; ³SKIN Center for Dermatology, Petersborough, ON, Canada; ⁴Hale University, New Haven, CT, USA; ⁵University of Lübeck, Lübeck, Germany; ⁶Fukuoka University Hospital, Fukuoka, Japan; ⁷UCSD School of Medicine, Los Angeles, CA, USA; ⁸Herakle Clinical Research, Wooloomooloo, Qld, Australia; ⁹Case Western Reserve University, Cleveland, OH, USA; ¹⁰Zhejiang University School of Medicine, Zhejiang, China; ¹¹Bristol Myers Squibb, Princeton, NJ, USA; ¹²Oregon Medical Research Center, Portland, OR, USA

This poster may not be reproduced without written permission from the authors.

Results

Baseline patient demographics and disease characteristics

- Baseline demographics and disease characteristics were largely similar across treatment groups in pooled data from the 2 trials (Table 1)

Methods

• Study designs
  - Table designs for POETYK PSO-1 and PSO-2 are summarized in Figure 2
  - Key eligibility criteria included the following:
    - Age ≥18 years
    - Diagnosis of moderate to severe plaque psoriasis
    - PASI ≥12, VFA ≥5, body surface area (%) ≥10%
  - Patient randomization was stratified by geographic region, body weight, and prior biologic use
  - Co-morbidities were the proportion of patients who achieved PASI 75 and PASA 0/1 responses vs placebo at Week 16

Conclusion

- The drug was efficacious and well tolerated in patients who switched from placebo to deucravacitinib at Week 16

References


Acknowledgments

Further acknowledgments are provided by R. Warren, M. Zheng, and A. Blauvelt.

Disclosures

- All authors report no conflicts of interest related to this work except R. Warren, M. Zheng, and A. Blauvelt.

         1

- P02-1

- P02-1

- P02-1

- P02-1

- P02-1

- P02-1

- P02-1

- P02-1